Bioaffinity Technologies, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the results of the 2026 Annual Meeting of Stockholders held on April 30, 2026. The Company, incorporated in Delaware, is an emerging growth company with its principal executive offices in San Antonio, Texas. The filing details the approval of ten proposals by stockholders, including significant capital structure adjustments and governance matters.
Key Financial Metrics and Capital Structure
The filing does not provide specific revenue, profit, cash flow, or debt metrics. However, it discloses the following capital structure data as of the Record Date (March 13, 2026):
- Shares Outstanding: 4,498,675 shares of Common Stock.
- Equity Plan Capacity: The 2024 Equity Incentive Compensation Plan share reserve was increased from 66,666 to 1,000,000 shares.
- Warrant Issuance Authority: Approval granted for the issuance of up to 271,500 shares upon exercise of August 2025 Warrants.
- Anti-Dilution Adjustments: Authority granted to increase shares issuable upon exercise of August 2025 Warrants by up to 365,620 shares and Series B Preferred Stock conversion by up to 131,884 shares, subject to price floors of $4.50 and $3.00 respectively.
Material Changes and Voting Results
Stockholders approved all ten proposals presented at the meeting. Key material changes include:
- Reverse Stock Split Authorization: Stockholders approved a reverse stock split with a ratio ranging from 1-for-2 to 1-for-250, to be determined by the Board of Directors.
- Non-Public Offerings: Authorization granted for securities issuance in non-public offerings under Nasdaq Marketplace Rule 5635(d), including potential change of control provisions.
- Director Elections: All six nominees (Maria Zannes, Steven Girgenti, Peter Knight, Jamie Platt, Roberto Rios, and John J. Oppenheimer) were elected to the Board.
- Accounting Firm: WithumSmith+Brown, PC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Outlook, Risks, and Management Commentary
The filing indicates that the Company has secured shareholder approval for significant flexibility in its capital structure, specifically regarding warrant exercises, anti-dilution adjustments, and potential reverse stock splits. The approval of the adjournment proposal (Proposal No. 10) was noted as unnecessary since all critical proposals were approved. The filing does not contain specific forward-looking guidance, risk factors, or management commentary beyond the voting results and the authorization of future corporate actions.
Investor Verification Checklist
- Reverse Split Ratio: Verify the specific ratio (1-for-2 to 1-for-250) the Board ultimately selects and the timing of the implementation.
- Warrant Exercise Terms: Confirm the final exercise prices and share counts following the approved anti-dilution adjustments for the August 2025 Warrants and Series B Preferred Stock.
- Non-Public Offering Details: Monitor for announcements regarding the specific terms, size, and pricing of any non-public offerings authorized under Proposal No. 7.
- Dilution Impact: Assess the potential dilution impact from the increased equity plan reserve (1,000,000 shares) and the authorized warrant/convertible share issuances.